The Oncology Institute Inc. (TOI)
NASDAQ (CM) NASDAQ (CM) Primary 
The Oncology Institute: Making Progress
The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.
The Oncology Institute, Inc. (TOI) Reports Q3 Loss, Beats Revenue Estimates
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.
Topicus: Rising To The Topicus Of VMS Supremacy In Europe
Topicus.com Inc. (TOI:CA) is a leading European vertical market software acquirer, benefiting from a fragmented European market and low Private Equity competition. TOI's record acquisition spending in 2025, strong organic growth, and successful AI integration position it for accelerated earnings and organic growth. Recent investments in Asseco Poland and Cipal Schaubroeck NV expand TOI's geographic reach and deepen its expertise in public sector and enterprise software.
The Oncology Institute: A Promising Company In A Growing Sector
The Oncology Institute has achieved a strong growth in revenue in the previous years, justifying its stock price movement. We believe TOI will still be able to grow in the coming quarters while currently trading at a discount. Risks remain high, warranting careful positioning.
The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Daniel Virnich - CEO & Executive Director Mark Hueppelsheuser - Corporate Participant General Counsel - Corporate Participant Robert Carter - Chief Financial Officer Conference Call Participants David Michael Larsen - BTIG, LLC, Research Division Robert Michael LeBoyer - NOBLE Capital Markets, Inc., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Operator Ladies and gentlemen, greetings, and welcome to the Oncology Institute Second Quarter 2025 Earnings Call.
The Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2025 Earnings Conference Call May 14, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - Chief Executive Officer Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG Yuan Zhi - B. Riley Bill Sutherland - The Benchmark Company Robert LeBoyer - NOBLE Capital Markets Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2025 Earnings Conference Call.
The Oncology Institute, Inc. (TOI) Q4 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Conference Call Participants Yuan Zhi - B. Riley Robert LeBoyer - NOBLE Capital Markets Operator Good afternoon, and welcome to The Oncology Institute's Fourth Quarter and Full-Year 2024 Earnings Conference Call.
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
